Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881376 | 0.90 | TRPV1 (0.46) | TRPV1KDM4EPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3877894 | 0.89 | HSD11B1 (0.47) | TRPV1HSD11B1TRPA1MEN1USP2 | |
| SCHEMBL13761246 | 0.83 | TRPV1 (0.45) | TRPV1RBP4HSD11B1TRPA1NPSR1 | |
| SCHEMBL3877898 | 0.83 | TRPV1 (0.45) | TRPV1RBP4HSD11B1TRPA1NPSR1 | |
| SCHEMBL3884819 | 0.81 | KDM4E (0.46) | TRPV1HSD11B1KDM4E | |
| SCHEMBL3891317 | 0.81 | KDM4E (0.46) | TRPV1MEN1USP2CASP1BRCA1 | |
| SCHEMBL3891483 | 0.80 | HSD11B1 (0.48) | TRPV1RBP4HSD11B1TRPA1PIK3CA | |
| SCHEMBL3880570 | 0.79 | KDM4E (0.48) | TRPA1KDM4EPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3878801 | 0.79 | KDM4E (0.48) | TRPV1KDM4E | |
| SCHEMBL3889211 | 0.77 | TRPV1 (0.46) | TRPV1RBP4HSD11B1NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | TRPV1 244/4885RBP4 2234/4885HSD11B1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.